European Meeting on Complement in Human Disease (EMCHD) 2017
APL-2, a Complement C3 Inhibitor, May Potentially Reduce Both Intravascular and Extravascular Hemolysis in Patients With Paroxysmal Nocturnal Hemoglobinuria
Landing
Back to Conference Resources
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.